Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

Table 1 Summary of patients included in analysis

Trial	Tumor type	Treatment (s)	n	Frequency of Toxicity [n= (%)]		Median PFS (months)
				HT ≥ grade 2	HFSR ≥ grade 2	HT < grade 2 vs. ≥ grade 2	Log-Rank P =	HFSR < grade 2 vs. ≥ grade 2	Log-Rank P =
APC-CRPC	mCRPC	Bevacizuamb + Thalidomide + Docetaxel	60	15 (25.0)	4 (6.7)	14.9 vs. 31.5	0.0009	N/A*	ND*
BAY-BEV	ST	Sorafenib + Bevacizumab	27	15 (55.6)	13 (48.1)	3.7 vs. 11.9	0.052	3.7 vs. 12.6	0.094
BAY-CRPC^†	mCRPC	Sorafenib	46	9 (19.6)	7 (15.2)	3.7 vs. 1.8	0.067	2.0 vs. 3.1	0.29
BAY-NSCLC	NSCLC	Sorafenib	22	9 (40.9)	10 (45.5)	1.9 vs. 4.6	0.19	2.9 vs. 3.7	0.38
BAY-CRC	CRC	Sorafenib + Cetuximab	18	1 (5.6)	2 (11.1)	N/A*	ND*	4.7 vs. 8.7	0.0065
BAY-KS^‡	KS	Sorafenib +/- Protease inhibitor	8	3 (37.5)	2 (25.0)	N/A*	ND*	N/A*	ND*

*Not done (ND). Patients were not evaluated in this analysis due to low frequency of toxicity (i.e. APC-CRPC vs. HFSR and BAY-CRC vs. HT) or due to limited PFS data (KS).
^†3 Patients participating on this trial were also treated on APC-CRPC.
^‡Two patients on BAY-KS trial received only sorafenib.
C: Caucasian, AA: African-American, Others: Hispanic or Asians, mCRPC: metastatic castrate resistant prostate cancer, NSCLC: non-small cell lung cancer, CRC: colorectal cancer, KS: Kaposi's sarcoma, ST: solid tumors, HFSR: hand-foot skin reaction syndrome, NA: not applicable

ISSN: 1756-9966